{"transactions":[{"id":804246,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":51895,"kind":"person","name":"Frankenius Equity AB","position":1,"cik":"0001988262","reported_name":"Frankenius Equity AB","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-04-20T20:36:46.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":false,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents conversion price pursuant to an offer (the \"Offer\") the Company commenced on June 23, 2025, under which all holders of Preferred Stock could exchange their shares of Preferred Stock for Common Stock equal to the sum of the liquidation preference per share price of $10.00 and all accrued and unpaid dividends per share outstanding through August 10, 2027, divided by a $4.00 conversion price per share."},{"field":"shares","element":"transactionShares","label":"F3","text":"On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 31, 2025, all 230,000 shares of Preferred Stock held by the Reporting Person were converted into 759,000 shares of Common Stock pursuant to the Offer."}],"balance_after":0,"derivative":{"exercise_price":4,"underlying":"Common Stock","underlying_shares":759000},"source":{"system":"sec-edgar","filing":"0001628280-26-026014","document":"wk-form4_1776717403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026026014/wk-form4_1776717403.xml","form_type":"4"}},{"id":804245,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":51895,"kind":"person","name":"Frankenius Equity AB","position":1,"cik":"0001988262","reported_name":"Frankenius Equity AB","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T20:36:46.000Z","date":"2025-07-31","kind":"exercise","planned":false,"acquired":true,"shares":759000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares received upon conversion of the Series A Preferred Stock (the \"Preferred Stock\") reported in Table II."}],"balance_after":6989748,"source":{"system":"sec-edgar","filing":"0001628280-26-026014","document":"wk-form4_1776717403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026026014/wk-form4_1776717403.xml","form_type":"4"}},{"id":1273370,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":51895,"kind":"person","name":"Frankenius Equity AB","position":1,"cik":"0001988262","reported_name":"Frankenius Equity AB","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-02-11T22:57:00.000Z","date":"2025-02-10","kind":"other","planned":false,"acquired":true,"shares":205853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The conversion price (the \"Conversion Price\") reflects the reset effective as of February 10, 2025, which reset occurred in accordance with the terms of the Issuer's Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of the Issuer filed with the Delaware Secretary of State on August 10, 2023."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Effective February 10, 2025, the Conversion Price of the 230,000 shares of Series A Convertible Preferred Stock (the \"Preferred Stock\") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective February 10, 2025, the Conversion Price of the 230,000 shares of Series A Convertible Preferred Stock (the \"Preferred Stock\") held by the Reporting Person was reset in accordance with the terms of the Preferred Stock, resulting in an increase in the number of shares of Common Stock issuable upon conversion of the Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 435,853 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"All then outstanding shares of Preferred Stock are automatically converted into shares of the Issuer's Common Stock on August 10, 2027."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"Represents the incremental number of shares of Common Stock that are issuable upon conversion of the Preferred Stock as a result of the Conversion Price reset."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"After giving effect to the Conversion Price reset, the Preferred Stock is convertible, in whole or in part, into 435,853 shares of Common Stock of the Issuer (based on a Conversion Price of $5.277 per share, which is subject to adjustment upon the occurrence of certain events) at any time, at the Reporting Person's election."}],"balance_after":435853,"derivative":{"exercise_price":5.277,"underlying":"Common Stock","underlying_shares":205853},"source":{"system":"sec-edgar","filing":"0001415889-25-003620","document":"form4-02112025_100256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826667/000141588925003620/form4-02112025_100256.xml","form_type":"4"}},{"id":1325090,"issuer":{"id":5872,"kind":"organization","name":"TriSalus Life Sciences, Inc.","symbol":"TLSI"},"owners":[{"id":51895,"kind":"person","name":"Frankenius Equity AB","position":1,"cik":"0001988262","reported_name":"Frankenius Equity AB","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-19T23:03:55.000Z","date":"2024-12-17","kind":"purchase","planned":false,"acquired":true,"shares":62972,"price":3.97,"value":249998.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued in connection with the closing of the transaction contemplated by the Securities Purchase Agreement, entered into December 12, 2024, by and between the Issuer and Reporting Person."}],"balance_after":6230748,"source":{"system":"sec-edgar","filing":"0001415889-24-029904","document":"form4-12192024_111252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826667/000141588924029904/form4-12192024_111252.xml","form_type":"4"}}]}